DK1506236T3 - Immunglobulin-frameworks, der udviser forbedret stabilitet i det intracellulære miljø og fremgangsmåder til identifikation deraf - Google Patents

Immunglobulin-frameworks, der udviser forbedret stabilitet i det intracellulære miljø og fremgangsmåder til identifikation deraf

Info

Publication number
DK1506236T3
DK1506236T3 DK03732434.0T DK03732434T DK1506236T3 DK 1506236 T3 DK1506236 T3 DK 1506236T3 DK 03732434 T DK03732434 T DK 03732434T DK 1506236 T3 DK1506236 T3 DK 1506236T3
Authority
DK
Denmark
Prior art keywords
immunglobulin
procedures
identification
improved stability
providing improved
Prior art date
Application number
DK03732434.0T
Other languages
Danish (da)
English (en)
Inventor
Kathrin Tissot
Stefan Ewert
Der Maur Adrian Auf
Dominik Escher
Alcide Barberis
Original Assignee
Esbatech A Novartis Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esbatech A Novartis Co Llc filed Critical Esbatech A Novartis Co Llc
Application granted granted Critical
Publication of DK1506236T3 publication Critical patent/DK1506236T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C07K2317/82—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK03732434.0T 2002-05-22 2003-05-21 Immunglobulin-frameworks, der udviser forbedret stabilitet i det intracellulære miljø og fremgangsmåder til identifikation deraf DK1506236T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38264902P 2002-05-22 2002-05-22
US43825603P 2003-01-03 2003-01-03
PCT/EP2003/005324 WO2003097697A2 (en) 2002-05-22 2003-05-21 Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same

Publications (1)

Publication Number Publication Date
DK1506236T3 true DK1506236T3 (da) 2013-03-04

Family

ID=29553590

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03732434.0T DK1506236T3 (da) 2002-05-22 2003-05-21 Immunglobulin-frameworks, der udviser forbedret stabilitet i det intracellulære miljø og fremgangsmåder til identifikation deraf
DK10009857.3T DK2332989T3 (en) 2002-05-22 2003-05-21 IMMUNGLOBULIN FRAMEWORKS PROVIDING IMPROVED STABILITY IN THE INTRACELLULAR ENVIRONMENT AND PROCEDURES FOR IDENTIFICATION THEREOF

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK10009857.3T DK2332989T3 (en) 2002-05-22 2003-05-21 IMMUNGLOBULIN FRAMEWORKS PROVIDING IMPROVED STABILITY IN THE INTRACELLULAR ENVIRONMENT AND PROCEDURES FOR IDENTIFICATION THEREOF

Country Status (14)

Country Link
US (5) US8853362B2 (show.php)
EP (5) EP2332989B1 (show.php)
JP (10) JP2006508638A (show.php)
CN (4) CN1662556B (show.php)
AU (2) AU2003238370B2 (show.php)
CA (2) CA2483285C (show.php)
CY (1) CY1114225T1 (show.php)
DK (2) DK1506236T3 (show.php)
ES (3) ES2399617T3 (show.php)
HU (1) HUE048922T2 (show.php)
NZ (1) NZ536412A (show.php)
PT (2) PT1506236E (show.php)
SI (2) SI2947095T1 (show.php)
WO (1) WO2003097697A2 (show.php)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0226727D0 (en) * 2002-11-15 2002-12-24 Medical Res Council Intrabodies
ES2375826T3 (es) 2005-03-25 2012-03-06 National Research Council Of Canada Método para aislamiento de polipéptidos solubles.
AU2011265593B2 (en) * 2005-06-07 2013-08-15 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
AU2016204739C1 (en) * 2005-06-07 2017-10-19 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
RS52861B (sr) 2005-06-07 2013-12-31 Esbatech - A Novartis Company Llc Stabilna i rastvorljiva antitela koja inhibiraju tnf (alfa)
AU2013207650B2 (en) * 2005-06-07 2016-04-21 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
EP2604627A1 (en) * 2006-04-28 2013-06-19 Delenex Therapeutics AG Antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK
CN103251947B (zh) * 2006-07-10 2017-11-21 艾斯巴技术-诺华有限责任公司 穿过上皮和/或内皮层的scFV抗体
CN101668771B (zh) * 2007-03-12 2013-08-21 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 单链抗体的基于序列的工程改造和最优化
WO2008131575A2 (en) * 2007-04-27 2008-11-06 Esbatech Ag Anti-alk antibodies suitable for treating metastatic cancers or tumors
PL2164961T3 (pl) 2007-06-25 2015-08-31 Esbatech Alcon Biomed Res Unit Oparta na sekwencjach inżynieria i optymalizacja przeciwciał jednołańcuchowych
PL2158315T3 (pl) * 2007-06-25 2016-10-31 Sposoby modyfikowania przeciwciał i zmodyfikowane przeciwciała o ulepszonych właściwościach funkcjonalnych
US8323647B2 (en) 2007-09-13 2012-12-04 Delenex Therapeutics Ag Humanized antibodies against the β-amyloid peptide
AU2015201794B2 (en) * 2008-06-25 2017-01-19 Novartis Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFa
EP2307457B2 (en) 2008-06-25 2022-06-22 Novartis AG Stable and soluble antibodies inhibiting tnf
ES2884117T3 (es) 2008-06-25 2021-12-10 Novartis Ag Optimización de la solubilidad de inmunoaglutinantes
AU2013202997B2 (en) * 2008-06-25 2015-01-22 Novartis Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFalpha
PL3628686T3 (pl) 2008-06-25 2022-02-28 Novartis Ag Humanizowanie przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
KR20180005753A (ko) 2008-06-25 2018-01-16 에스바테크 - 어 노바티스 컴파니 엘엘씨 Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
AU2016273957C1 (en) * 2008-06-25 2019-04-18 Novartis Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFa
HUE047678T2 (hu) * 2008-06-25 2020-05-28 Novartis Ag Nyúl ellenanyagok humanizálása univerzális ellenanyagváz alkalmazásával
TR201808591T4 (tr) * 2008-06-25 2018-07-23 Esbatech Alcon Biomed Res Unit Bir evrensel bir antikor iskeleti kullanılarak tavşan antikorların insanlaştırılması.
US8637022B2 (en) 2008-06-30 2014-01-28 Esbatech, An Alcon Biomedical Research Unit Llc Functionalized polypeptides
CA2730178A1 (en) 2008-07-10 2010-01-14 Esbatech, An Alcon Biomedical Research Unit Llc Methods and compositions for enhanced delivery of macromolecules
WO2010096941A1 (en) 2009-02-24 2010-09-02 Esbatech, An Alcon Biomedical Research Unit Llc Methods for identifying immunobinders of cell-surface antigens
KR102059866B1 (ko) * 2009-02-24 2019-12-27 에스바테크 - 어 노바티스 컴파니 엘엘씨 세포-표면 항원의 면역결합제를 동정하는 방법
US8399624B1 (en) 2009-06-25 2013-03-19 Esbatech, An Alcon Biomedical Research Unit Llc Acceptor framework for CDR grafting
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
EP2476754A1 (en) * 2011-01-14 2012-07-18 Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts Methods for the identification and repair of amino acid residues destabilizing single-chain variable fragments (scFv)
CN103890246A (zh) 2011-08-18 2014-06-25 亲和生物科学公司 可溶性多肽
UY34404A (es) 2011-10-20 2013-05-31 Esbatech A Novartis Co Llc Anticuerpo estable unido a múltiples antígenos
KR101732552B1 (ko) * 2012-08-22 2017-05-08 재단법인 목암생명과학연구소 안정화된 면역글로불린가변도메인 선별방법 및 선별된 도메인의 응용
EP2914287B1 (en) 2012-11-05 2020-03-18 Delenex Therapeutics AG Binding members to il-1 beta
EP4001307A1 (en) 2012-12-17 2022-05-25 Cell Medica Inc. Antibodies against il-1 beta
AU2013378628A1 (en) 2013-02-15 2015-06-11 Esbatech - A Novartis Company Llc Acceptor framework for CDR grafting
HK1219485A1 (zh) * 2013-02-20 2017-04-07 Esbatech - A Novartis Company Llc 用於cdr移植的受体框架
SG10201913751RA (en) 2013-05-06 2020-03-30 Scholar Rock Inc Compositions and methods for growth factor modulation
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
US20170306046A1 (en) 2014-11-12 2017-10-26 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN114470193B (zh) * 2015-10-13 2024-08-30 优瑞科生物技术公司 对人类cd19具有专一性的抗体药剂和其用途
EP3365364B1 (en) 2015-10-23 2024-04-10 Eureka Therapeutics, Inc. Antibody/t-cell receptor chimeric constructs and uses thereof
CN108463248B (zh) 2015-11-12 2022-10-21 西雅图基因公司 聚糖相互作用化合物及使用方法
US11434294B2 (en) 2016-02-25 2022-09-06 Cell Medica, Inc. Binding members to PD-L1
PH12019500609B1 (en) * 2016-09-21 2024-02-21 Aptevo Res & Development Llc Cd123 binding proteins and related compositions and methods
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CA3054939A1 (en) 2017-03-03 2018-09-07 Seattle Genetics, Inc. Glycan-interacting compounds and methods of use
CN112218621A (zh) * 2018-04-10 2021-01-12 西北大学 包含基于靶向亲和域的膜蛋白的胞外囊泡
WO2020069349A1 (en) * 2018-09-27 2020-04-02 Colorado State University Research Foundation Scfv's for live cell imaging and other uses
US12285437B2 (en) 2019-10-30 2025-04-29 The Research Foundation For The State University Of New York Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity
PH12023550015A1 (en) 2020-07-16 2024-03-11 Novartis Ag Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
KR20230154994A (ko) 2021-03-10 2023-11-09 마빌론 아게 Tdp-43에 대한 항체 및 이의 용도
US20250101089A1 (en) 2022-01-24 2025-03-27 Cambridge Enterprise Limited Tau therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US5817311A (en) * 1993-03-05 1998-10-06 Universite Catholique De Louvain Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
DE4425115A1 (de) 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
US6696248B1 (en) * 1995-08-18 2004-02-24 Morphosys Ag Protein/(poly)peptide libraries
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
US6262238B1 (en) 1997-01-14 2001-07-17 Roche Diagnostic, Gmbh Process for modifying the stability of antibodies
EP1040201A4 (en) 1997-11-28 2001-11-21 Invitrogen Corp SINGLE CHAIN MONOCLONAL ANTIBODY FUSION AGENTS THAT REGULATE IN VIVO TRANSCRIPTION
GB2344886B (en) 1999-03-10 2000-11-01 Medical Res Council Selection of intracellular immunoglobulins
DK1242457T3 (da) * 1999-12-28 2004-12-20 Esbatech Ag Intracellulære antistoffer [intracellulære antistoffer] med defineret struktur, der er stabil i et reducerende miljö, og anvendelse deraf
GB0008419D0 (en) 2000-04-05 2000-05-24 Bioinvent Int Ab A method for invitro molecular evolution of antibody function
EP1156062A1 (en) 2000-05-12 2001-11-21 GPC Biotech AG Immunomodulatory human MHC class II antigen-binding peptides/proteins
US6410271B1 (en) 2000-06-23 2002-06-25 Genetastix Corporation Generation of highly diverse library of expression vectors via homologous recombination in yeast
DE10039191C1 (de) 2000-08-10 2002-01-17 Infineon Technologies Ag Hochfrequenz-Eingangsstufe

Also Published As

Publication number Publication date
JP2013078343A (ja) 2013-05-02
PT1506236E (pt) 2013-03-27
HK1071378A1 (en) 2005-07-15
WO2003097697A2 (en) 2003-11-27
ES2399617T3 (es) 2013-04-02
ES2656427T3 (es) 2018-02-27
CA2483285A1 (en) 2003-11-27
CN1662556B (zh) 2013-05-01
DK2332989T3 (en) 2015-05-11
AU2010202634B2 (en) 2012-08-23
JP2017201990A (ja) 2017-11-16
EP2332989B1 (en) 2015-04-01
US8853362B2 (en) 2014-10-07
PT2332989E (pt) 2015-08-05
AU2003238370B2 (en) 2010-04-29
CN105175535A (zh) 2015-12-23
EP2947095B1 (en) 2019-10-02
CY1114225T1 (el) 2016-08-31
HK1152320A1 (en) 2012-02-24
US20060035320A1 (en) 2006-02-16
NZ536412A (en) 2008-10-31
AU2003238370A1 (en) 2003-12-02
HUE048922T2 (hu) 2020-09-28
CA2867542A1 (en) 2003-11-27
JP2020171286A (ja) 2020-10-22
AU2010202634A1 (en) 2010-07-15
JP6075836B2 (ja) 2017-02-08
CN103739706B (zh) 2015-11-18
JP2019058191A (ja) 2019-04-18
JP6918033B2 (ja) 2021-08-11
CN102093477A (zh) 2011-06-15
US20200165322A1 (en) 2020-05-28
EP2332989A1 (en) 2011-06-15
JP6100544B2 (ja) 2017-03-22
EP2314622A1 (en) 2011-04-27
CA2867542C (en) 2020-04-14
CN1662556A (zh) 2005-08-31
US10125186B2 (en) 2018-11-13
JP6261136B2 (ja) 2018-01-17
HK1217712A1 (en) 2017-01-20
US20150057191A1 (en) 2015-02-26
JP2013256533A (ja) 2013-12-26
CA2483285C (en) 2015-01-27
US20190119361A1 (en) 2019-04-25
CN102093477B (zh) 2014-02-26
SI2332989T1 (sl) 2015-06-30
JP2006508638A (ja) 2006-03-16
US20170107272A1 (en) 2017-04-20
JP2012228272A (ja) 2012-11-22
EP2947095A1 (en) 2015-11-25
JP2015214583A (ja) 2015-12-03
SI2947095T1 (sl) 2020-04-30
US9518108B2 (en) 2016-12-13
EP1506236B1 (en) 2013-01-23
JP2015227372A (ja) 2015-12-17
JP2010187678A (ja) 2010-09-02
WO2003097697A3 (en) 2004-12-09
EP1506236A2 (en) 2005-02-16
EP2314622B1 (en) 2017-10-18
ES2537104T3 (es) 2015-06-02
US10570190B2 (en) 2020-02-25
CN103739706A (zh) 2014-04-23
EP3656787A1 (en) 2020-05-27

Similar Documents

Publication Publication Date Title
DK1506236T3 (da) Immunglobulin-frameworks, der udviser forbedret stabilitet i det intracellulære miljø og fremgangsmåder til identifikation deraf
IS7520A (is) Pyrimidínonefnasambönd, samsetningar og aðferðir
DK1480955T3 (da) O-cyclopropyl-carboxanilider og deres anvendelse som fungicider
NO20052855D0 (no) Fosfonoksykinazolinderivater og farmasoytisk anvendelse derav.
NO20053356D0 (no) Aminindazolderivater og anvendelse derav som kinaseinhibitorer.
NO20055568D0 (no) Substituerte 1,4-diazepiner og anvendelser derav
IS7881A (is) CHK-, PDK- og AKT-hindrandi pýrimidín, framleiðsla þeirra og notkun sem lyfjaefni
DK1511734T3 (da) Forbindelser, præparater og fremgangsmåder
NO20053974D0 (no) Tienopyrimidinforbindelser og anvendelse derav.
DK2298288T4 (da) Overtrukket tabletformulering og fremgangsmåde
IS8422A (is) Bensímídasólafleiður, efnablöndur sem innihalda þær, framleiðsla þeirra og notkun þeirra
DK1560826T3 (da) Pyridopyrimidinonderivater, fremgangsmåde til fremstiling heraf og farmaceutiske sammensætninger indeholdende disse
DK1667668T3 (da) Alfabeta3 og altabeta6-integrinantagonister som antifibrotiske midler
IS8219A (is) Bensímídasólafleiður, efnablöndur sem innihalda þær, framleiðsla þeirra og notkun
IS7798A (is) Efnasambönd, lyfjablöndur og aðferðir
IS8528A (is) Sveppadeyðandi blöndur byggðar á karbamatafleiðum og skordýraeitri
DK1753725T3 (da) Tetra-hydro-iso-quinolinsulfonamidderivater, fremstilling og terapeutisk anvendelse heraf.
DK1651607T3 (da) 6-(1,1-difluoralkyl)-4-aminopicolinater og deres anvendelse som herbicider
DK1768691T3 (da) Aequorinholdige præparater og fremgangsmåder til anvendelse af samme
DK1400566T3 (da) Bindemiddel til co-ekstrudering baseret på co-podet metallocen-polyethylen og LLDPE, SBS og PE
NO20052478D0 (no) Vitamin D-analoger, sammensetninger omfattende analogene og deres anvendelse.
FI20040484L (fi) Palonsammutusmenetelmä, -laitteisto ja -väline
IS7694A (is) Sterasamrunaefnasambönd, framleiðsla og notkun þeirra
NO20053805D0 (no) Diarylmetylindenpiperidinderivater, framgangsmate for fremstilling derav, og anvendelse derav
NO20055142D0 (no) Diarylmetylidenpiperidinderivater, fremstillinger og anvendelser derav